- ►hematologylibrary.org - Free from Publisher M Leporrier, S Chevret, B Cazin, N Boudjerra … - …, 2001 - bloodjournal.hematologylibrary.org Since 1980, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) has conducted
3 multicenter prospective randomized clinical trials in previously untreated patients with CLL
in which different therapeutic strategies were designed according to the baseline (A, B, C) ... Cited by 252 - Related articles - BL Direct - All 6 versions
- ►hematologylibrary.org - Free from Publisher T Robak, JZ Blonski, M Kasznicki, M … - …, 2000 - bloodjournal.hematologylibrary.org B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of leukemia in adults in
Europe and North America. 1 It is a disease for which there is no cure, and it mainly affects persons
older than 50. The disease is characterized by a variable clinical course, and the overall ... Cited by 141 - Related articles - BL Direct - All 5 versions
- ►ascopubs.org BD Cheson, DA Vena, J Barrett, B … - Journal of Clinical …, 1999 - jco.ascopubs.org PURPOSE: The nucleoside analogs fludarabine, 2'-deoxycoformycin (DCF), and 2-chlorodeoxyadenosine
(CdA), commonly used in the treatment of patients with indolent lymphoid malignancies such
as chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL), are associated ... Cited by 131 - Related articles - BL Direct - All 6 versions
- ►bloodjournal.org FR Mauro, R Foa, R Cerretti, D Giannarelli, S Coluzzi, F … - Blood, 2000 - Am Soc Hematology Although the association of AHA with CLL is well known, the literature is based mainly on small
series of patients or on isolated case reports. Thus, there is limited information on the clinical
features and outcome of these patients. Up to now, no established standard therapy for ... Cited by 129 - Related articles - BL Direct - All 6 versions
- ►free.fr [PDF] MS Lionakis, DP Kontoyiannis - The Lancet, 2003 - Elsevier Since the 1990s, opportunistic fungal infections have emerged as a substantial cause of morbidity
and mortality in profoundly immunocompromised patients. Hypercortisolaemic patients, both
those with endogenous Cushing's syndrome and, much more frequently, those receiving ... Cited by 120 - Related articles - All 12 versions
JG Perkins, JM Flynn, RS Howard, JC … - CA A Cancer Journal for … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 86 - Related articles - BL Direct - All 3 versions
- ►ascopubs.org VA Morrison, KR Rai, BL Peterson, JE Kolitz, … - Journal of Clinical …, 2001 - jco.ascopubs.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook
Add to Reddit Add to Technorati Add to Twitter What's this? ... From the Veterans Affairs Medical
Center, Minneapolis, MN; Long Island Jewish Medical Center, New Hyde Park, and North ... Cited by 80 - Related articles - BL Direct - All 8 versions
GR Donowitz, DG Maki, CJ Crnich, PG … - …, 2001 - asheducationbook. … Infection in the neutropenic patient has remained a major clinical challenge for over three
decades. While diagnostic and therapeutic interventions have improved greatly during this
period, increases in the number of patients with neutropenia, changes in the etiologic ... Cited by 74 - Related articles - All 3 versions
- ►hematologylibrary.org SN O'Brien, N Blijlevens, TH Mahfouz, … - …, 2003 - asheducationbook. … One of the most common complications involved in treating patients with hematologic cancer
is infection. In many cases there are multiple factors that predispose these patients to infections
such as neutropenia induced by therapy or bone marrow involvement, ... Cited by 64 - Related articles - All 4 versions
KA Thursky, LJ Worth, JF Seymour, H … - British journal of …, 2006 - jspinaldisorderstechs.com There is an increasing use of monoclonal antibodies in the treatment of haematological
malignancies. Alemtuzumab (Campath-1H; Ilex Pharmaceuticals, San Antonio, TX, USA) is a
monoclonal antibody reactive with the CD52 antigen used as first and second line ... Cited by 67 - Related articles - Cached - BL Direct - All 6 versions
